Lexeo Therapeutics adds Dr. Laura Sepp-Lorenzino to board

Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.

Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Appointment date: April 28, 2026 Board term end: 2028 annual meeting Annual cash compensation: $40,000 +3 more

6 metrics

Appointment date April 28, 2026 Effective date of Dr. Sepp-Lorenzino’s board appointment

Board term end 2028 annual meeting Scheduled expiration of director term

Annual cash compensation $40,000 Yearly cash fee for non-employee board service

Initial stock option grant 50,000 shares Option award granted on appointment date

Annual option grant 25,000 shares Expected yearly option grant starting with 2027 annual meeting

Director age 65 Age of Dr. Sepp-Lorenzino at appointment

Key Terms

Non-Employee Director Compensation Policy, indemnification agreement, Item 404(a) of Regulation S-K, Science and Technology Committee, +1 more

5 terms

Non-Employee Director Compensation Policy financial

"In accordance with the Company’s Non-Employee Director Compensation Policy (the “Director Compensation Policy”)"

indemnification agreement regulatory

"The Company has entered into its standard form of indemnification agreement with Dr. Sepp-Lorenzino"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

Item 404(a) of Regulation S-K regulatory

"any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

Science and Technology Committee financial

"appointed Dr. Sepp-Lorenzino as a member of the Company's Science and Technology Committee"

Annual Grant financial

"including an annual option to purchase 25,000 shares, effective on the date of each annual meeting of the stockholders (the “Annual Grant”)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexeo Therapeutics (LXEO) announce in this 8-K filing?

Lexeo Therapeutics announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. She will serve until the 2028 annual meeting and join the Science and Technology Committee, bringing extensive genomic medicine and biopharmaceutical leadership experience.

Who is Dr. Laura Sepp-Lorenzino, the new Lexeo Therapeutics (LXEO) director?

Dr. Laura Sepp-Lorenzino is a biochemist and industry leader who has held senior roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck. She now leads GNMmeds LLC and serves on several biotech boards, adding deep genomic medicine and RNA therapeutics expertise to Lexeo.

What compensation will Dr. Sepp-Lorenzino receive as a Lexeo Therapeutics (LXEO) director?

Under Lexeo’s non-employee director compensation policy, Dr. Sepp-Lorenzino will receive $40,000 in annual cash compensation for board service. She also received an initial stock option for 50,000 shares and is eligible for future annual option grants of 25,000 shares, subject to policy terms.

When will Dr. Sepp-Lorenzino receive annual equity grants from Lexeo Therapeutics (LXEO)?

Annual option grants of 25,000 shares begin with the 2027 annual meeting of stockholders. Because her appointment date is within six months of the 2026 annual meeting, the policy makes her ineligible for an annual grant tied to the 2026 meeting, delaying recurring awards until 2027.

Does Dr. Sepp-Lorenzino have any related-party transactions with Lexeo Therapeutics (LXEO)?

Other than Lexeo’s standard indemnification agreement, the company states Dr. Sepp-Lorenzino has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no such transactions are currently proposed, limiting potential related-party concerns.

Are there special arrangements behind Dr. Sepp-Lorenzino’s appointment to Lexeo Therapeutics (LXEO)?

Lexeo states there are no arrangements or understandings with any persons under which Dr. Sepp-Lorenzino was appointed as director, and no family relationships with existing directors or executive officers. This indicates a standard, independent board appointment process consistent with typical corporate governance practice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 07:00 AM EDT Learn about SEC filing dates

0001907108false00019071082026-04-282026-04-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2026

Lexeo Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41855	85-4012572
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
345 Park Avenue South, Floor 6
New York, New York				10010
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 212 547-9879

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LXEO		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of New Director

On April 28, 2026 (the “Appointment Date”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”). Dr. Sepp-Lorenzino will serve as a director with a term of office expiring at the Company’s 2028 Annual Meeting of Stockholders. As of the Appointment Date, the Board also appointed Dr. Sepp-Lorenzino as a member of the Company's Science and Technology Committee. Dr. Sepp-Lorenzino, age 65, has served as Principal of GNMmeds LLC, a consulting firm focused on genomic medicine research and development, since January 2025. Dr. Sepp-Lorenzino has also served as a member of the boards of directors of Taysha Gene Therapies, Inc., a publicly traded biotechnology company, since November 2020, AskBio Inc., a wholly owned, independently operated subsidiary of Bayer AG, since April 2025, and URSA Medicines, a private biotech company, since September 2025. Dr. Sepp-Lorenzino previously served as Executive Vice President, Chief Scientific Officer of Intellia Therapeutics, Inc., a publicly traded biotechnology company, from May 2019 to January 2025 and as Scientific Advisor until December 2025. From 2017 to May 2019, Dr. Sepp-Lorenzino served as Vice President, Head of Nucleic Acid Therapies at Vertex Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Dr. Sepp-Lorenzino previously held roles at Alnylam Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2014 to 2017, and at Merck & Co., a publicly traded pharmaceutical company, in Oncology and RNA Therapeutics from 1999 to 2014. Dr. Sepp-Lorenzino holds a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and an M.S. and Ph.D. in biochemistry from New York University.

In accordance with the Company’s Non-Employee Director Compensation Policy (the “Director Compensation Policy”), Dr. Sepp-Lorenzino is eligible to participate in the Company’s standard compensation arrangements for non-employee directors which consists of cash and equity compensation for service on the Board. Pursuant to the Director Compensation Policy, Dr. Sepp-Lorenzino is entitled to $40,000 in annual cash compensation for service on the Board with additional cash compensation payable for committee service. In addition, pursuant to the Director Compensation Policy, Dr. Sepp-Lorenzino was granted an initial stock option award for 50,000 shares on the Appointment Date and is expected to be granted additional equity awards consistent with the terms of the Director Compensation Policy, including an annual option to purchase 25,000 shares, effective on the date of each annual meeting of the stockholders (the “Annual Grant”). However, because the Appointment Date is within six months of the 2026 annual meeting of stockholders, under the Director Compensation Policy, Dr. Sepp-Lorenzino will not be eligible to receive an Annual Grant in connection with the 2026 annual meeting of the stockholders and will first be eligible to receive an Annual Grant in connection with the 2027 annual meeting of stockholders.

There are no arrangements or understandings between Dr. Sepp-Lorenzino and any other persons pursuant to which Dr. Sepp-Lorenzino was appointed a director of the Company, and there are no family relationships between Dr. Sepp-Lorenzino and any director or executive officer of the Company.

The Company has entered into its standard form of indemnification agreement with Dr. Sepp-Lorenzino, a copy of which is filed as Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-274777) on September 29, 2023. Other than the indemnification agreement, Dr. Sepp-Lorenzino has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Lexeo Therapeutics, Inc.
Date:	April 30, 2026	By:	/s/ R. Nolan Townsend
			R. Nolan Townsend, Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB